SAS supports life sciences companies during transformational era
Leader in health analytics continues to provide technology innovation in 35th year of industry collaboration
DIA 2011 CONFERENCE, CHICAGO (Jun. 20, 2011) – Facing growing financial, regulatory, and research challenges, the life sciences industry continues to grow its decades-long reliance on SAS, the leader in business analytics, for breakthrough innovation.
SAS' unique data integration and advanced analytics solutions for life sciences have proven crucial for companies coping with data growth, increasingly sophisticated analytical requirements, and the growing need for cross-industry partnerships. Over the past 12 months:
"Advanced analytics are critical in facilitating transformation in life sciences," said Alan Louie, Research Director, IDC Health Insights' Clinical Development, Strategy and Technology service. "The advanced capabilities in SAS' solutions are a strong testament of the company's industry leadership and shows that SAS will remain a leading contributor to industry success."
For more than 34 years, life sciences companies have chosen SAS to access, manage and analyze research and operational data to improve drug discovery, expedite product development, and mitigate risks.
In support of that close, historical relationship and the transformation changes underway across the industry, SAS recently formed a new team of industry experts representing pharma, clinical research, health services and payers. The Center for Health Analytics and Insights (CHAI) is exploring innovative applications of advanced analytics in areas such as adaptive clinical trials and showcasing how other industries have applied advanced analytics in support of business transformation.
"The need of the moment is a collaborative and comprehensive approach that uses health analytics to resolve common pains across the pharma, health plans and care delivery sectors," said CHAI Managing Director Jason Burke. "We have the team—with more than 250 years of industry experience—to help transition the industry to new operating models."
Life sciences and healthcare represent one of SAS's largest business segments. SAS is the choice of 100 percent of the FORTUNE Global 500® life sciences companies. Eli Lilly, Daiichi Sankyo and Alcon are among the leading pharmaceutical companies that use SAS.
Today's news was announced at the annual meeting of the Drug Information Association (DIA) in Chicago. SAS, exhibiting in booth 1349, is participating in the event's interoperability showcase, which simulates how health information is seamlessly passed from care providers to facilitate clinical research and safety reporting.
SAS in Health Analytics
SAS is the industry leader in health analytics software and services, delivering best-in-class solutions for improving medical care, strengthening financial performance, deepening customer relationships, and pursuing medical innovations. All of the top 25 health plans and pharmaceutical companies depend on SAS® for strategic insights into health outcomes, profitability, and customer preferences and behaviors that produce useful intelligence for business transformation and growth.
SAS is the leader in business analytics software and services, and the largest independent vendor in the business intelligence market. Through innovative solutions delivered within an integrated framework, SAS helps customers at more than 50,000 sites improve performance and deliver value by making better decisions faster. Since 1976 SAS has been giving customers around the world
The Power to Know®